Evidence map›Paper›PMID 27844028›Full record

ReviewOpen forum infectious diseases2016

How to Pitch an Antibiotic Stewardship Program to the Hospital C-Suite.

Brad Spellberg, John G Bartlett, David N Gilbert

Abstract readReview
In one paragraph

Review in Open forum infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Deep Dive Into Gaps and Barriers to Implementation of Antimicrobial Stewardship Programs in Hospitals in Latin America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Antimicrobial ethicists: Making ethics explicit in antimicrobial stewardship.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2021
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Brad SpellbergLos Angeles County-University of Southern California (LAC + USC) Medical Center;; Department of Medicine, Division of Infectious Diseases, Keck School of Medicine at University of Southern California, Los Angeles.
John G BartlettDivision of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland.
David N GilbertDivision of Infectious Diseases, Providence Portland Medical Center , Oregon.

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
Transferrin Combination Therapy to Address Antimicrobial ResistanceR01AI117211 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SPELLBERG, BRAD J · 2016 to 2019
$2.7M
NIAID NIH HHS R01 AI117211NIAID NIH HHS UM1 AI104681
6 · The paper itself

Abstract

Hospitals will soon require antibiotic stewardship programs. Infectious diseases specialists must craft business plans to engage hospital leadership to fund such programs. In this article, we review key cost and revenue elements that should be covered in such plans. Society is placing increasing emphasis on the importance of antimicrobial stewardship programs (ASPs). New regulatory standards require hospitals to implement ASPs. Infectious Diseases (ID) specialists will need to help design and implement such programs at hospitals. A critical component of establishing such programs is submitting a business plan to hospital leadership justifying the cost and structure of the ASP and explaining what benefits the hospital will gain in return. In this article, we explore typical elements of such business plans and describe how hospital leadership may evaluate and determine the value of such plans. Understanding hospital costs and revenue models is critical to creating a viable and realistic business plan to support ASPs.

Indexed as

Antibiotic stewardship programbusiness plancost efficacyC-suitehospital.

Identifiers

PMID27844028
PMCPMC5104972

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.